OverviewSuggest Edit

AoBiome is a Cambridge, MA based biotech company working on the science of Ammonia Oxidizing Bacteria (AOB) and human health. AoBiome does primary research, collaborates, with others on research and develops applications to positively impact skin conditions and reduce systemic inflammation.

TypePrivate
Founded2013
HQCambridge, US
Websiteaobiome.com

Latest Updates

Employees (est.) (Oct 2020)18(+6%)
Cybersecurity ratingBMore

Key People/Management at AOBiome

Todd Krueger

Todd Krueger

President & CEO, Director
Jun Wang

Jun Wang

Chairman
Jamie Heywood

Jamie Heywood

Director and Founder
Ioannis Gryllos

Ioannis Gryllos

Vice President of Manufacturing Operations and Quality
Annalisa Jenkins

Annalisa Jenkins

Director
Jim Hoffman

Jim Hoffman

SVP of Strategic Alliances and Communications, Director
Show more

AOBiome Office Locations

AOBiome has an office in Cambridge
Cambridge, US (HQ)
125 Cambridgepark Dr
Cambridge, US
One Broadway, 1 Broadway
Show all (2)

AOBiome Financials and Metrics

Summary Metrics

Founding Date

2013

AOBiome total Funding

$38.7 m

AOBiome latest funding size

$30 m

Time since last funding

4 years ago

AOBiome investors

AOBiome's latest funding round in January 2017 was reported to be $30 m. In total, AOBiome has raised $38.7 m
Show all financial metrics

AOBiome Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

AOBiome Online and Social Media Presence

Embed Graph

AOBiome News and Updates

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Mass., June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus...

AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema

CAMBRIDGE, Mass., Jan. 2, 2019 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, ...

AOBiome Frequently Asked Questions

  • When was AOBiome founded?

    AOBiome was founded in 2013.

  • Who are AOBiome key executives?

    AOBiome's key executives are Todd Krueger, Jun Wang and Jamie Heywood.

  • How many employees does AOBiome have?

    AOBiome has 18 employees.

  • Who are AOBiome competitors?

    Competitors of AOBiome include Vyome Biosciences, Oncologie and Lion TCR.

  • Where is AOBiome headquarters?

    AOBiome headquarters is located at 125 Cambridgepark Dr, Cambridge.

  • Where are AOBiome offices?

    AOBiome has an office in Cambridge.

  • How many offices does AOBiome have?

    AOBiome has 2 offices.